Aldeyra Therapeutics Stock Price, News & Analysis (NASDAQ:ALDX) $3.24 +0.12 (+3.85%) (As of 12:45 PM ET) Add Compare Share Share Today's Range$3.05▼$3.2550-Day Range$1.47▼$6.6852-Week Range$1.42▼$11.97Volume338,557 shsAverage Volume1.35 million shsMarket Capitalization$190.58 millionP/E RatioN/ADividend YieldN/APrice Target$12.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Aldeyra Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside295.3% Upside$12.33 Price TargetShort InterestHealthy5.59% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.19Based on 6 Articles This WeekInsider TradingSelling Shares$4.45 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.76) to ($1.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector540th out of 949 stocksPharmaceutical Preparations Industry238th out of 421 stocks 3.3 Analyst's Opinion Consensus RatingAldeyra Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.33, Aldeyra Therapeutics has a forecasted upside of 295.3% from its current price of $3.12.Amount of Analyst CoverageAldeyra Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.59% of the float of Aldeyra Therapeutics has been sold short.Short Interest Ratio / Days to CoverAldeyra Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aldeyra Therapeutics has recently decreased by 5.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAldeyra Therapeutics does not currently pay a dividend.Dividend GrowthAldeyra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALDX. Previous Next 1.8 News and Social Media Coverage News SentimentAldeyra Therapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Aldeyra Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 17 people have searched for ALDX on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aldeyra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,453,308.00 in company stock.Percentage Held by InsidersOnly 7.30% of the stock of Aldeyra Therapeutics is held by insiders.Percentage Held by Institutions66.62% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aldeyra Therapeutics are expected to decrease in the coming year, from ($0.76) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aldeyra Therapeutics is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aldeyra Therapeutics is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAldeyra Therapeutics has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aldeyra Therapeutics Stock (NASDAQ:ALDX)Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Read More ALDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALDX Stock News HeadlinesDecember 5, 2023 | finance.yahoo.comShould You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings?December 5, 2023 | americanbankingnews.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Significant Decrease in Short InterestDecember 6, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 2, 2023 | americanbankingnews.comResearch Analysts Set Expectations for Aldeyra Therapeutics, Inc's FY2023 Earnings (NASDAQ:ALDX)November 28, 2023 | bizjournals.comLexington biotech gets second FDA rejection this yearNovember 28, 2023 | msn.comFDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional StudyNovember 27, 2023 | msn.comFDA says more data needed to approve Aldeyra dry eye drug (update)November 27, 2023 | finance.yahoo.comAldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseDecember 6, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 1, 2023 | benzinga.comWhat's Going On With Aldeyra Therapeutics Stock?November 1, 2023 | investorplace.comWhy Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?October 19, 2023 | benzinga.com10% Owner of Aldeyra Therapeutics Makes $4.45M SaleOctober 18, 2023 | msn.comOppenheimer Downgrades Aldeyra Therapeutics (ALDX)October 18, 2023 | msn.comBiotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & MoreOctober 17, 2023 | finance.yahoo.comAldeyra (ALDX) Plummets on Dry Eye Disease Drug's SetbackOctober 17, 2023 | proactiveinvestors.comAldeyra Therapeutics stock tanks on warning that FDA will reject new drug applicationOctober 17, 2023 | markets.businessinsider.comCiti Analyst Retains Buy Rating for Aldeyra Therapeutics Despite FDA Concerns and Revised ProjectionsOctober 16, 2023 | nasdaq.comAldeyra Therapeutics Falls After FDA Indicated Addl. Clinical Trial For Reproxalap For Dry EyeOctober 16, 2023 | msn.comAldeyra says FDA may not approve dry eye drug, stock plunges 63%October 16, 2023 | benzinga.comWhy Aldeyra Therapeutics (ALDX) Stock Is Getting ObliteratedSeptember 29, 2023 | markets.businessinsider.comFINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses to Contact the FirmSeptember 28, 2023 | stockhouse.comDEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the FirmSeptember 28, 2023 | tmcnet.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)September 26, 2023 | businesswire.comDeadline Alert: ALDX Investor Alert: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Aldeyra Therapeutics, Inc. Class Action LawsuitSeptember 25, 2023 | stockhouse.comFRIDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the FirmSeptember 24, 2023 | prnewswire.comALDX FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDXSeptember 18, 2023 | msn.comEyeing Returns: Aldeyra's Shift From Lab To MarketSee More Headlines Receive ALDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/27/2021Today12/06/2023Next Earnings (Estimated)12/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALDX CUSIPN/A CIK1341235 Webwww.ampliphibio.com Phone781-761-4904Fax781-270-0630Employees15Year FoundedN/APrice Target and Rating Average Stock Price Target$12.33 High Stock Price Target$15.00 Low Stock Price Target$8.00 Potential Upside/Downside+295.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.77% Return on Assets-28.01% Debt Debt-to-Equity Ratio0.02 Current Ratio6.81 Quick Ratio6.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book1.21Miscellaneous Outstanding Shares58,820,000Free Float54,528,000Market Cap$183.52 million OptionableOptionable Beta1.40 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesTodd C. Brady (Age 48)M.D., Ph.D., Chief Executive Officer and Director Joshua Reed (Age 47)Chief Financial Officer David McMullin (Age 45)Chief Commercial Officer James A. Gow (Age 53)M.D., Senior Vice President of Clinical Development Stephen G. Machatha (Age 43)Ph.D., Senior Vice President, Technical Operation Key CompetitorsMerrimack PharmaceuticalsNASDAQ:MACKVerastemNASDAQ:VSTMStoke TherapeuticsNASDAQ:STOKAlimera SciencesNASDAQ:ALIMAtai Life SciencesNASDAQ:ATAIView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Sold 9,329 shares on 11/30/2023Ownership: 0.019%Deutsche Bank AGBought 6,470 shares on 11/24/2023Ownership: 0.501%Graham Capital Management L.P.Bought 10,123 shares on 11/22/2023Ownership: 0.017%Wolverine Trading LLCBought 39,808 shares on 11/16/2023Ownership: 0.034%AQR Capital Management LLCSold 5,245 shares on 11/15/2023Ownership: 0.036%View All Insider TransactionsView All Institutional Transactions ALDX Stock Analysis - Frequently Asked Questions Should I buy or sell Aldeyra Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALDX shares. View ALDX analyst ratings or view top-rated stocks. What is Aldeyra Therapeutics' stock price target for 2024? 3 brokerages have issued 12-month price objectives for Aldeyra Therapeutics' stock. Their ALDX share price targets range from $8.00 to $15.00. On average, they expect the company's stock price to reach $12.33 in the next twelve months. This suggests a possible upside of 295.3% from the stock's current price. View analysts price targets for ALDX or view top-rated stocks among Wall Street analysts. How have ALDX shares performed in 2023? Aldeyra Therapeutics' stock was trading at $6.96 at the beginning of 2023. Since then, ALDX shares have decreased by 55.2% and is now trading at $3.12. View the best growth stocks for 2023 here. Are investors shorting Aldeyra Therapeutics? Aldeyra Therapeutics saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 3,160,000 shares, a decline of 5.7% from the October 31st total of 3,350,000 shares. Based on an average daily volume of 2,520,000 shares, the short-interest ratio is presently 1.3 days. Currently, 5.6% of the shares of the stock are sold short. View Aldeyra Therapeutics' Short Interest. When is Aldeyra Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, December 7th 2023. View our ALDX earnings forecast. How were Aldeyra Therapeutics' earnings last quarter? Aldeyra Therapeutics, Inc (NASDAQ:ALDX) announced its quarterly earnings data on Wednesday, October, 27th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.01. During the same period in the prior year, the business posted ($0.23) earnings per share. What ETF holds Aldeyra Therapeutics' stock ? Invesco Dorsey Wright Healthcare Momentum ETF holds 172,465 shares of ALDX stock, representing 0.81% of its portfolio. What other stocks do shareholders of Aldeyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). Who are Aldeyra Therapeutics' major shareholders? Aldeyra Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Laurion Capital Management LP (1.92%), Eagle Asset Management Inc. (1.77%), Deutsche Bank AG (0.50%), Deutsche Bank AG (0.50%), Rafferty Asset Management LLC (0.46%) and Ameriprise Financial Inc. (0.34%). Insiders that own company stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc and Todd C Brady. View institutional ownership trends. How do I buy shares of Aldeyra Therapeutics? Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ALDX) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.